In summary, these findings demonstrate that hfCas13d‐mediated PLK1 suppression is capable of substantially attenuating the in vivo tumour growth of osteosarcoma xenografts, potentially through the regulation of Smad3 activity. The gene discussed is PLK1; the disease is osteosarcoma.